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INTRODUCTION
Effective immunosuppression without any adverse reaction
is one of the most important objective of organ transplanta-
tion. Calcineurin inhibitor based immunosuppression regi-
mens have been widely used and improved graft survival with
reducing the episode of acute rejection. However, it may have
serious complications such as life-threatening infections and
increased incidence of cancer. New strategies are still needed
to obtain the elusive goal of donor-specific immunosuppres-
sion and tolerance by the host to toward foreign graft. There-
fore, achieving immune tolerance is regarded as the goal in
the field of transplantation. 
Allograft rejection requires robust T cell activation and
proliferation. For the full activation of T cells, costimulation
is necessary. Blockade of the CD28-B7 and/or CD40-CD154
pathways significantly prolonged allograft survival of both
rodents and primate models by reducing acute allograft rejec-
tion (1-10). Although many successful results of prolonging
allograft survival in murine models were reported, some strains
of mice such as C57BL/6 showed relatively resistant to these
types of treatment and allograft rejection with near normal
kinetics (11-13). IL-2 plays an important role in clonal expan-
sion and continuing viability of activated T lymphocytes.
Depleting IL-2 or blocking its receptor (IL-2R) can reduce
the acute rejection and enhance the allograft survival (14-16).
However, single use of IL-2 pathway blocking agent is not
sufficient to delay acute rejection and improve graft survival
(17). Thus, IL-2 pathway blocking methods were used in com-
bination with other immunosuppressive modalities such as
calcineurin inhibitors in clinical transplantation or with cos-
timulation blocking agent and reported prolonged allograft
survival even in costimulation blockade resistant strain (11). 
A proven method to produce robust transplantation toler-
ance is the induction of donor hematopoietic chimerism. Some
previous studies had reported successful and prolonged allo-
graft survival using this method (18, 19). However, it needs
large dose of irradiation or cytoablative agents such as cyclo-
phosphamide to make niche for the engraftment of donor
bone marrow (BM) cells in recipient bone marrow. Recent-
ly, costimulation blocking agents were used to reduce radia-
tion dose and drugs and some studies reported prolonged
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IL-2 Pathway Blocking in Combination with Anti-CD154 Synergistically
Establishes Mixed Macrochimerism with Limited Dose of Bone 
Marrow Cells and Prolongs Skin Graft Survival in Mice
To facilitate the establishment of mixed chimerism with limited dose of bone marrow
(BM) cells, and to achieve tolerance in skin graft model, combined blocking of co-
stimulatory pathway and IL-2 pathway was used in minimally myeloablative model
using busulfan. BM cells (2.5× ×10
7) of BALB/c were injected into C57BL/6 mice at
day 0 with full thickness skin graft after single dose injection of busulfan (25 mg/kg)
on day -1. Recipients were grouped and injected the anti-CD154, CTLA4-Ig, anti-IL-
2R at days 0, 2, 4, and 6 according to protocol. Mixed macrochimerism were induced
in groups treated with anti-CD154+anti-CTLA4-Ig, anti-CD154+anti-IL-2R, and anti-
CD154+anti-CTLA4 Ig+anti-IL-2R. Three groups having chimerism enjoyed pro-
longed graft survival more than 6 months. Superantigen deletion study revealed
deletion of alloreactive T cells in combined blockade treated groups. In graft versus
host disease model using CFSE staining, CD4+ T cell and CD8+ T cell prolifera-
tion were reduced in groups treated with CTLA4-Ig or anti-IL-2R or both in combi-
nation with anti-CD154. However, anti-IL-2R was not so strong as CTLA4-Ig in terms
of inhibition of T cell proliferation. In conclusion, IL-2 pathway blocking combined
with anti-CD154 can establish macrochimerism with limited dose of BM transplan-
tation and induce specific tolerance to allograft.
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graft survival (20-23). Using costimulatory blocking agents
combined with administration of megadoses of non-T cell
depleted bone marrow achieved chimerism without pretrans-
plant conditioning (21, 23). However, large dose of bone mar-
row under protection of costimulatory blocking agent is not
suitable for the clinical application in the setting of deceased
donor transplantation since the total number of BM cells are
limited. Use of busulfan in combination with costimulatory
blockade was introduced to reduce toxicity and induce titrat-
able degrees of macrochimerism to induce tolerance without
cytoreductive preconditioning (20, 24). Until now, most of
the studies have used anti-CD154 mAb and cytotoxic T-lym-
phocyte antigen 4 immunoglobulin (CTLA-Ig) as costimu-
lation blockades, and this combination treatment with BM
transplantation always achieved stable chimerism in differ-
ent studies (20-24). 
We postulated that simultaneous blockade of costimula-
tory pathway with anti-CD154 and IL-2 pathway followed
by donor bone marrow transplantation could promote titra-
ble, high-level of macrochimerism with single dose of busul-
fan and limited numbers of bone marrow cells and could
achieve at least comparable results to anti-CD154 and CTLA4-
Ig treatment. If it is successful, it could be easily applicable
in clinical settings with less toxicity of conventional immuno-
suppression and induce specific tolerance to donor organs
resulting in prolonged graft survival. 
MATERIALS AND METHODS
Mice
Adult male BALB/c (H-2d) and C57BL/6 (H-2b) mice, each
weighing 20 g were obtained from Orient Co. (Sungnam
city, Korea) and housed in specific pathogen free conditions
under the guidance of institutional guidelines for animal care
and welfare. 
Bone marrow preparation and treatment regimens
Bone marrow cells were obtained from tibiae, femurs, and
humeri of BALB/c mice using sterile saline flush. After lysis
of red blood cells (RBC) with Trizma base ammonium chlo-
ride (TBAC) solution, single cell suspensions were made and
resuspended at 2.5×107 cells/0.4 mL of sterile saline and
injected via penile vein of recipient mice (C57BL/6) on day
0. For recipient preparation, busulfan (Busulfex
�, Jeil-Kirin
Pharm. Inc., Seoul, Korea) (25 mg/kg) was administered on
day -1. Anti-IL-2R mAb (PC61 clone [ATCC:TIB 222]:
250  g/day), hamster anti-mouse CD154 mAb (MR1; 500
g/day) and CTLA4-Ig (500  g/day) were administered on
days 0, 2, 4, and 6. All the antibodies were purchased from
Bioexpress Co. (Lebanon, NH, U.S.A.). Recipient mice were
grouped by treatment regimens, such as BM+busulfan, group
I: BM+busulfan+anti-CD154, group II; BM+busulfan+
anti-CD154+anti-IL-2R, group III; BM+busulfan+anti-
CD154+CTLA Ig, group IV; and BM+busulfan+anti-CD
154+CTLA4 Ig+anti-IL-2R, as group V.
Skin grafting
Full thickness skin grafts (1 cm2) of dorsum of BALB/c ear
were transplanted on dorsal thorax of C57BL/6 mice on day
0 after injection of bone marrow cells, and secured with Band-
Aid
� (Johnson & Johnson, Arlington, TX, U.S.A.) for 7 days.
After removal of Band-Aid, graft survival was observed every-
day. Rejection was defined as complete loss of graft tissue.
Flow cytometric analysis
Whole peripheral blood of recipients was obtained from
tail vein and stained with flurorochrome-conjugated antibody
(Abs) (anti-CD3e, anti-H-2Kd, anti-H-2Kb, anti-CD25, anti-
CD4, anti-V 8.1/8.2, anti-V 5.1/2, anti-V 11; Becton
Dickinson, San Diego, CA, U.S.A.) followed by RBC lysis
and washing with whole blood lysis kit (R&D System, Min-
neapolis, MN, U.S.A.). Stained cells were analyzed with Cell
Quest software on a FACScaliber flow cytometer (Becton Dic-
kinson, Mountain View, CA, U.S.A.).
Measure of T cell proliferation (CFSE staining)
T cells from each recipient group were obtained with a Pan
T cell isolation kit (Miltenyi Biotec, Auburn, CA, U.S.A.)
followed by RBC lysis using TBAC solution (pH 7.6) from
recipient spleens and resuspended on 5  M carboxyfluorescein
diacetate succinimidyl ester (CFSE) (Molecular Probes, Eug-
ine, OR, U.S.A.) solution to attach CFSE probes. Single cell
suspension labeled with CFSE (2×107 cells) was injected into
a vein of BALB/c mice which had been supralethally irradiated
with 1,800 rad of total dose. After 66 hr, spleens from BALB/
c mice were procured and single cell suspension was obtained
with same manner as described above. Those single cell sus-
pensions were stained with anti-CD4 and anti-CD8 Ab (Cal-
tag, Burlingame, CA, U.S.A.) and analyzed by flow cytometry.
RESULTS
Stable mixed chimerism was achieved by the treatment of
single dose of busulfan and costimulatory signal blockade
We examined the ability of single dose of busulfan and BM
cells to promote hemopoietic chimerism in allograft model.
After two weeks from bone marrow transplantation, we had
checked the formation of mixed chimerism and ratio from
peripheral blood. The mixed chimerism was described as per-
cent ratio of H-2Kd positive T cells to total CD3e+ T cells.Mixed chimerisms were rarely shown in group I (0.78±0.20
%) and group II (6.50±0.71%). However, in group III, IV
and V, we found relatively high ratio of mixed chimerism
formation at two weeks (34.23±8.31%, 24.48±3.03%,
24.54±2.68%). The ratio of bone marrow chimerism inc-
reased until 4 months after the bone marrow transplantation,
then, became plateau for whole periods of experiment with
range of 65% to 75% ratio (Fig. 1). From this result we con-
firmed that anti-CD154 alone could not achieve chimerism
with limited dose of BM cells, and addition of anti-IL-2R
worked synergistically. Anti-IL-2R alone could not induce
chimerism in preliminary experiment (data not shown).
Prolongation of skin graft survival in chimeric mice
Donor specific allograft survival was observed using skin
graft to see if chimeric animal accept graft without rejection.
In group I, which received bone marrow only, could not pro-
long graft survival (median survival time [MST], 11 days).
Anti-CD154 alone prolonged graft survival modestly (MST,
21 days), however, all the grafts failed eventually with lim-
ited dose of bone marrow. On the contrary, graft survival of
group III, IV and V, to which anti-IL-2R or CTLA4-Ig or
both were added, showed graft survival of more than 6 months
(Fig. 2). Anti-IL-2R alone could not prolong graft survival
and rejected rapidly as in control group in preliminary experi-
ment (data not shown).
Clonal deletions of alloreactive T cells in chimeric animals
as the mechanism of tolerance maintenance
In normal condition, BALB/c mice delete V 11 and V
5.1/2 positive CD4
+ T cells in the thymus due to their high
affinity for endogenous retroviral superantigens (mouse mam-
mary tumor virus [MMTV]) presented by I-E MHC class II
molecules, whereas C57BL/6 mice do not express I-E and uti-
lize 4-5% of V 11 positive CD4
+ T cells and 2-3% of V
5.1/5.2 positive CD4
+ T cells. Both BALB/c and C57BL/ 6
mice have 15-20% of CD4
+ T cells which express V 8.1/8.2
(37, 38). Six months after the skin graft, we checked allore-
active T cell deletion of each group using flow cytometric
analysis (Fig. 3). The group II, which had been administered
anti-CD154 only, has both CD4
+ V1 1
+ T cells (3.80±1.50
%) and CD4
+ V5
+ T cells (1.14±0.73%). In group III, IV,
and V which had additional anti-IL-2R or CTLA4 Ig or both,
CD4
+ T cells which express V 11
+ and V 5
+ were deleted
almost completely compared to normal level (V 11; 1.05±
0.35% vs. 0.79±0.21% vs. 0.94±0.34%, V 5; 0.39±0.16
% vs. 0.25±0.13% vs. 0.54±0.23%). However, CD4
+V8
+
T cells in all groups showed persistently. This means that
chimeric BALB/c cells deleted donor reactive recipient T cells
in the thymus. 
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Fig. 1. Mixed chimerism was measured from peripheral blood of
C57BL/6 recipients having BALB/c BM cells. Percentages of do-
nor-derived T cells to the total number of T cells were expressed.
Groups are allogeneinc bone marrow transplantation with busul-
fan only (    ; n=6), treated with anti-CD154 (    ; n=4), anti-CD154
and anti-IL-2R (    ; n=5), anti-CD154 and CTLA4-Ig (    ; n=8), anti-
CD154, anti-IL-2R and CTLA-4 Ig (    ; n=8).
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Fig. 2. Survival of skin allografts. Combined use of costimulation
blockade achieved indefinite graft survival. Groups are allogeneinc
bone marrow transplantation with busulfan only (    ; n=6), treated
with anti-CD154 (    ; n=4), anti-CD154 and anti-IL-2R (    ; n=5),
anti-CD154 and CTLA4-Ig (    ; n=8), anti-CD154, anti-IL-2R and
CTLA-4 Ig (    ; n=8).
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Fig. 3. The utilization of V 5, V 8 and V 11 by CD4+ T cells in
peripheral blood of control (C57BL/6,     ; BALB/c,     ) and treat-
ed mice. Allogeneic bone marrow transplant with busulfan (    ).
C57BL/6 recipients were treated with anti-CD154 (    ; n=6), anti-
CD154 and anti-IL-2R Ab (    ; n=6), anti-CD154 and CTLA4-Ig (    ;
n=8), anti-CD154, anti-IL-2R and CTLA4-Ig (    ; n=8).1008 J.-H. Lee, J. Ha, S.-H. Kim, et al.
T cell proliferation was inhibited with costimulation block-
ade in graft versus host disease model
To evaluate if the donor specific T cell proliferation is inhib-
ited, T cells were harvested from recipient groups and con-
trol mice 2 months after transplantation. CFSE stained T cells
were administrated to supralethally irradiated BALB/c mice
(1,800 rad). After 66 hr of in vivo proliferation, T cells were
harvested from spleens of BALB/c mice and flow cytometric
analysis was performed followed by anti-CD4 and anti-CD8
stain. As a result, proliferation of T cells was minimal in groups
IV and V. Anti-IL-2 R further suppressed the proliferation
of T cells in group III compared to group II, but it could not
fully prevent T cell division from allostimulation. In group
V, CTLA4-Ig already inhibited T cell proliferation and anti-
IL-2R had no additional effect on that. CD4
+ and CD8
+ T
cells were fully proliferated in the other groups and normal
control (Fig. 4). 
DISCUSSION
The development of clinically applicable strategies to in-
duce a state of mixed hematopoietic chimerism for the treat-
ment of genetic hematologic diseases and to induce a state
of specific immunological tolerance to organ allograft has
received increasing attention over the past several years. After
initial reports by Sachs and colleagues (25, 26), many studies
reported the therapeutic potential of hematopoietic chimerism
to induce tolerance in adult animal models (27-29). In spite
of many successful reports, there were some problems concern-
ing the potential for over immunosuppression, loss of mem-
ory (non specific peripheral T cell depeletion), and/or enhanced
risk of malignancy with whole body irradiation which may
limit the clinical applications of these protocols (20). To reduce
the risk of preconditioning, supraphysiological doses of non-
T cell-depleted donor bone marrow transplantation method
under costimulation blockade was developed and induced a
robust state of donor specific tolerance (21, 23). Although
these methods could avoid the toxicity of preconditioning,
they also have problems in using very high numbers of BM
cells which would be impractical in clinical practice.
Undepleted T cells have increased the risk of lethal graft
versus host disease (GVHD), and relatively low level of chi-
merism was achieved (23). Although GVHD could be in-
hibited by the use of costimulation blockade, megadoses of
T cells were necessary to achieve titrable macrochimerism.
Because of these reasons, these protocols seem to be clinical-
ly unacceptable for deceased donor organ transplantation in
which the available amounts of bone marrow cells are limit-
ed (20). Theoretically, using T cell-depleted BM cells is bet-
ter than using whole BM cells. However, we could achieve
good level of chimerism as other reports which used T cell-
depleted BM cells (20). Durham et al. (21) also could achieve
similar level of chimerism without any evidence of GVHD
in repeated injection of BM cells experiment. In the recent report
of Adams et al. (24), they also used non-T cell-depleted BM
cells and achieved similar level of chimerism. Actually, it was
found in preliminary experiment that the level of chimerism
was similar between non T cell-depleted BM transplantation
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Fig. 4. (A) Representative samples from a flow cytometric assay
for T cell proliferation in vivo. Supralethally irradiated BALB/c mice
received CFSE-labeled T cells from naive and treated mice. Cells
were harvested at 66 hr after infusion. (B) Percentage of precursor
cells which divided 4 or more times. A
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group and T cell-depleted BM transplantation group (data
not shown).
There were several trials to make niche in the bone mar-
row to facilitate the engraftment of transplanted BM cells,
such as irradiation or using cytotoxic drugs (22, 28). How-
ever, irradiation achieved more than 90% of chimerism even
in very small amount of irradiation, which was just like sub-
stitution of recipient bone marrow with donor BM cells. Re-
cently, busulfan was introduced as a regimen which makes
stable chimerism (20). Busulfan has superiority to irradiation
since it does not show any residual effect. Furthermore, it has
less toxicity than irradiation and preserves white blood cell
counts better than irradiation (20). Previous studies used sin-
gle dose of busulfan (day 5) and two doses of BM cells (days
0 and 6) (20, 24). However, in clinical situation, donor bone
marrow is not enough for two dose and also difficult to keep
for a week. Therefore, we tried to use limited numbers of BM
cells as single dose injection with minimal preconditioning
using single dose of busulfan (25 mg/kg) one day before ad-
ministration of BM cells. 
Anti-CD154 only could not induce stable chimerism in
this study, which was different from high dose BM cell infu-
sion report in which BM cells were infused up to 90 days (21).
Therefore, large numbers of BM cells are necessary to induce
chimerism in situation with limited blocking of costimula-
tion signals. Although anti-IL-2R alone could not achieve
titrable BM chimerism (data not shown), BM chimerisms
were successfully induced in groups III, IV, and V. Therefore,
anti-IL-2R and CTLA4-Ig synergistically worked with anti-
CD154 to induce stable chimerism. Ratio of BM chimerism
was increased by 4 months and maintained with range of 65
to 75%. This mixed chimerism was stable until the end of
experiment (more than 300 days). This result is identical with
previous megadose BM cell infusion study or two dose BM
cell infusion study (20, 21, 24). As other reports, combined
use of anti-CD154 and CT- LA4-Ig seems to be perfect match
to induce stable chimerism and graft tolerance (20, 24). How-
ever, CTLA4-Ig is patented product and preclinical and clini-
cal studies are still on going. On the other hand, anti-IL-2R
is used in clinics everyday, and using anti-IL-2R is at least
comparable to using CTLA4-Ig in combination with anti-
CD154. Therefore, it would be easier to use anti-IL-2R than
CTLA4-Ig when other costimulation blockade would be avai-
lable.
In previous report by Jones et al., IL-2 pathway blocking
combined with costimulation blockade was able to enhance
graft survival in a costimulation resistant rejection model (11).
Although Dai et al. reported that, in transplant setting, IL-
2 plays important role in the elimination of alloreactive T
cells by enhancing activation induced cell death (30), com-
bined use of anti-IL-2R and costimulation blockade effectively
blocked the generation of alloreactive T cells (11). However,
without BM cell infusion, blocking of IL-2 pathway com-
bined with anti-CD154 and CTLA4-Ig could not achieve
tolerance and failed the graft eventually. 
Clonal deletion of donor specific alloreactive T cells is cor-
ner stone of robust immune tolerance and it is the main me-
chanism of inducing central tolerance. To compare the donor
specific deletion, we compared the utilization of V 11, V
5.1/2, and V 8.1/2 by CD4+T cells in B6 recipients among
groups. As previously expressed, BALB/c BM cells and com-
bined blocking of costimulation signals deleted V 11- and
V 5.1/2- bearing T cells. Our data show that the clonal dele-
tion of alloreactive T cells is the main mechanism of induc-
ing tolerance in BM mixed chimerism model, which is con-
sistent with other reports (20, 21, 24). 
Another major problem in inducing BM mixed chimerism
is GVHD. Ferrara et al. reported that in vivo administration
of anti-IL-2R can ameliorate the acute GVHD in bone mar-
row transplantation (31). In our data, CFSE staining analy-
sis showed that the proliferation of CD4+ T cell and CD8+
T cell were absent in groups treated with CTLA-4 Ig and
anti-IL-2R in GVHD model. Combined use of costimula-
tion blockade inhibited the proliferation of alloreactive T cells
which was also a part of mechanism of tolerance induction.
IL-2 pathway blocking only is less effective in preventing
allograft rejection. Similar results in different models were
reported in previous studies from Jones and others (11). Al-
though combined use of anti-CD154 and anti-IL-2R pro-
longed graft survival and showed stable mixed chimerism,
the proliferation study showed a certain portion of prolifer-
ated alloreactive T cells. This may suggest that this group
should be observed very long time to see if they regain allore-
activity, or there is an operational tolerance or ignorance even
with the presence of alloreactive T cells. There is also a pos-
sibility that active regulation of T cells with regulatory T
cells might exist. From the reports that blocking CD154-
CD40, CD28-B7 and IL-2R pathways result in down regu-
lation of T cell proliferation and induce regulatory T cell pro-
liferation, we could recognize that the proliferation of regu-
latory T cell is controlled by costimulatory molecules (32-
34). This should be explored in next experiment. Although
anti-IL-2R are not strong enough to block the proliferation
of alloreactive T cells than CTLA4-Ig, it showed compara-
ble results in terms of graft survival with using CTLA4-Ig.
Although further studies using large animals and primates
should follow, we can utilize mixed chimerism model with
minimal myeloablation strategies and limited dose of BM
cells to prolong the graft survival and induce tolerance. Com-
bined use of costimulation blockade together with anti-IL-
2R could be a nontoxic regimen in inducing tolerance. 
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